Welcome to our book review site go-pdf.online!
You may have to Search all our reviewed books and magazines, click the sign up button below to create a free account.
Cardiotoxicity of Oncologic Treatments
The possibility of getting a cardiovascular disease or cancer increases with advancing age. At the same time, relevant improvements in cancer therapy have resulted in the improvement of quality of life and the increasement of the survival rate of such patients. As a result we have larger number of patients that experience the cardiac side effects of chemotherapy. The extent of cardiotoxicity is variable, depending on the type of drug used, combination with other drugs, prior mediastinal radiotherapy and the presence of cardiovascular risk factors or history of heart disease. Early detection of the patients proneness for developing cardiotoxicity is the key issue to decrease morbidity and mortality. It also facilitates more tailored therapeutic interventions. Therefore, the collaboration and interaction of cardiology and oncology may contribute to reducing the cardiovascular adverse effects and improving the results in the treatment of patients with cancer.
Cardiovascular Complications in Cancer Therapy
This proposed text is designed to provide a useful and comprehensive resource and state-of-the-art overview to readers about vascular damage potentially induced by antineoplastic drugs. Thanks to more and more effective antineoplastic treatments the survival of cancer patients is enormously increasing, but at the same time it is increasing the burden of related cardiovascular complications that affect morbidity and mortality. On this basis a new branch of cardiology has been developed, that is Cardio-Oncology. The aim is to prevent cardiovascular complications related to cancer therapy and to facilitate and avoid interruption of antineoplastic drugs due to the occurrence of cardiovascular da...
Cardiotoxicity of Oncologic Treatments
The possibility of getting a cardiovascular disease or cancer increases with advancing age. At the same time, relevant improvements in cancer therapy have resulted in the improvement of quality of life and the increasement of the survival rate of such patients. As a result we have larger number of patients that experience the cardiac side effects of chemotherapy. The extent of cardiotoxicity is variable, depending on the type of drug used, combination with other drugs, prior mediastinal radiotherapy and the presence of cardiovascular risk factors or history of heart disease. Early detection of the patients proneness for developing cardiotoxicity is the key issue to decrease morbidity and mortality. It also facilitates more tailored therapeutic interventions. Therefore, the collaboration and interaction of cardiology and oncology may contribute to reducing the cardiovascular adverse effects and improving the results in the treatment of patients with cancer.
Electrocardiology 92
This volume consists of proceedings divided into 7 sections with a total of 89 papers. The proceedings are contributed by leading European, N American and Japanese researchers in this field. Recent works in various aspects of electrocardiology are discussed including mathematical modeling, cardial electrophysiology, cardiac arrhythmias, body surface mapping, computer applications, diagnostic criteria, ambulatory monitoring, conduction defects, etc. With the latest developments in the field of electrocardiology explored, this book will interest, inform and benefit doctors, physicists and computer scientists as well.
Mitochondrial Dysfunction Caused by Drugs and Environmental Toxicants
Developed as a one-stop reference source for drug safety and toxicology professionals, this book explains why mitochondrial failure is a crucial step in drug toxicity and how it can be avoided. • Covers both basic science and applied technology / methods • Allows readers to understand the basis of mitochondrial function, the preclinical assessments used, and what they reveal about drug effects • Contains both in vitro and in vivo methods for analysis, including practical screening approaches for drug discovery and development • Adds coverage about mitochondrial toxicity underlying organ injury, clinical reports on drug classes, and discussion of environmental toxicants affecting mitochondria
Circulation
None
